Key Insights

Highlights

Success Rate

72% trial completion

Published Results

34 trials with published results (10%)

Research Maturity

92 completed trials (27% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

10.2%

35 terminated out of 342 trials

Success Rate

72.4%

-14.1% vs benchmark

Late-Stage Pipeline

7%

24 trials in Phase 3/4

Results Transparency

37%

34 of 92 completed with results

Key Signals

34 with results72% success35 terminated

Data Visualizations

Phase Distribution

298Total
Not Applicable (79)
Early P 1 (8)
P 1 (62)
P 2 (125)
P 3 (22)
P 4 (2)

Trial Status

Completed92
Recruiting79
Unknown75
Terminated35
Active Not Recruiting30
Withdrawn16

Trial Success Rate

72.4%

Benchmark: 86.5%

Based on 92 completed trials

Clinical Trials (342)

Showing 20 of 20 trials
NCT07569263Phase 1Not Yet RecruitingPrimary

IL-8 Receptor Modified Patient-Derived Activated CD70 CAR T Cell Therapy in Adults With Brain Metastases

NCT04246879Not ApplicableActive Not RecruitingPrimary

MRI Following Stereotactic Radiosurgery (SRS) for Brain Metastases

NCT07197632Not ApplicableRecruitingPrimary

ioMRI in the Surgery of Brain Metastases.

NCT04084431Not ApplicableWithdrawnPrimary

Supportive Care With or Without Repeated Whole Brain Radiotherapy in Patients With Recurrent Brain Metastases

NCT05871307Not ApplicableRecruitingPrimary

Neoadjuvant vs. Intraoperative vs. Adjuvant Resection Cavity Radiotherapy of Brain Metastases

NCT06101069Not ApplicableRecruiting

Development of MRF for Characterization of Brain Tumors After Radiotherapy

NCT06466720Active Not RecruitingPrimary

Measuring and Mapping Cognitive Decline After Brain Radiosurgery

NCT05045950Phase 2RecruitingPrimary

Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

NCT07539753Phase 2Not Yet Recruiting

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

NCT03775330Active Not RecruitingPrimary

Radiosurgery With or Without Whole Brain Radiation for Multiple Metastases

NCT04689048Phase 1Recruiting

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

NCT04192981Phase 1Active Not RecruitingPrimary

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

NCT05786924Phase 1Recruiting

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

NCT07462507Phase 2Recruiting

Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

NCT03163368Early Phase 1Active Not RecruitingPrimary

Dose Escalation Trial of Neoadjuvant Radiosurgery for the Treatment of Metastatic Brain Tumors

NCT05013892Phase 2RecruitingPrimary

NTS-WBRT in Brain Metastases

NCT05064280Phase 2RecruitingPrimary

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

NCT06015295Not ApplicableRecruitingPrimary

A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

NCT06649058Phase 2RecruitingPrimary

EXCLAIM: Exploring Combined Local and Systemic Approaches In Brain Metastasis: a Multi-cohort Randomized Phase II Study Evaluating Initial Response to Systemic Therapy and Subsequent Integration of Stereotactic Radiosurgery in Patients With Low-risk Brain Metastases and Central Nervous System-active

NCT03550391Phase 3RecruitingPrimary

Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Scroll to load more

Research Network

Activity Timeline